Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
revised:
29
10
2023
received:
27
09
2023
accepted:
21
11
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Progression prediction is a significant unmet need in people with progressive multiple sclerosis (pwPMS). Studies on glial fibrillary acidic protein (GFAP) have either been limited to single center with relapsing MS or were based solely on Expanded Disability Status Scale (EDSS), which limits its generalizability to state-of-the-art clinical settings and trials applying combined outcome parameters. Serum GFAP and NfL (neurofilament light chain) were investigated in EmBioProMS participants with primary (PP) or secondary progressive MS. Six months confirmed disability progression (CDP) was defined using combined outcome parameters (EDSS, timed-25-foot walk test (T25FW), and nine-hole-peg-test (9HPT)). 243 subjects (135 PPMS, 108 SPMS, age 55.5, IQR [49.7-61.2], 135 female, median follow-up: 29.3 months [17.9-40.9]) were included. NfL (age-) and GFAP (age- and sex-) adjusted Z scores were higher in pwPMS compared to HC (p < 0.001 for both). 111 (32.8%) CDP events were diagnosed in participants with ≥3 visits (n = 169). GFAP Z score >3 was associated with higher risk for CDP in participants with low NfL Z score (i.e., ≤1.0) (HR: 2.38 [1.12-5.08], p = 0.025). In PPMS, GFAP Z score >3 was associated with higher risk for CDP (HR: 2.88 [1.21-6.84], p = 0.016). Risk was further increased in PPMS subjects with high GFAP when NfL is low (HR: 4.31 [1.53-12.13], p = 0.006). Blood GFAP may help identify pwPPMS at risk of progression. Combination of high GFAP and low NfL levels could distinguish non-active pwPMS with particularly high progression risk.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Aktion Multiple Sklerose Erkrankter Landesverband (AMSEL)
Organisme : Bayerische MS-Stiftung
Organisme : Deutschen Multiple Sklerose Gesellschaft
Informations de copyright
© 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246-257.
Meier S, Willemse EAJ, Schaedelin S, et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 2023;80(3):287-297.
Gafson AR, Jiang X, Shen C, et al. Serum neurofilament light and multiple sclerosis progression independent of acute inflammation. JAMA Netw Open. 2022;5(2):e2147588.
Leppert D, Kropshofer H, Haring DA, et al. Blood neurofilament light in progressive multiple sclerosis: post hoc analysis of 2 randomized controlled trials. Neurology. 2022;98(21):e2120-e2131.
Jiang X, Shen C, Teunissen CE, et al. Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation. Mult Scler. 2023;29(9):1070-1079.
Huss A, Otto M, Senel M, Ludolph AC, Abdelhak A, Tumani H. A score based on NfL and glial markers may differentiate between relapsing-remitting and progressive MS course. Front Neurol. 2020;11:608.
Abdelhak A, Hottenrott T, Morenas-Rodriguez E, et al. Glial activation markers in CSF and serum from patients with primary progressive multiple sclerosis: potential of serum GFAP as disease severity marker? Front Neurol. 2019;10:280.
Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798.
Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158-172.
Abdelhak A, Huss A, Stahmann A, et al. Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): design of a prospective observational multicentre pilot study. Contemp Clin Trials Commun. 2020;18:100574.
Robinson T, Abdelhak A, Bose T, et al. Cerebrospinal fluid biomarkers in relation to MRZ reaction status in primary progressive multiple sclerosis. Cell. 2020;9(12):2543.
Barro C, Healy BC, Liu Y, et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(1):e200052.
Abdelhak A, Krumbholz M, Senel M, et al. Patient-centered approach might effectively tackle the definition of progression in chronic neurological diseases: results from the EmBioProMS trial in progressive multiple sclerosis. medRxiv. 2021;2021.2009.2007.21262777.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
Ohle LM, Ellenberger D, Flachenecker P, et al. Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry. Sci Rep. 2021;11(1):13340.
Koch MW, Cutter GR, Giovannoni G, et al. Comparative utility of disability progression measures in PPMS: analysis of the PROMiSe data set. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e358.
Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209-220.
Healy LM, Stratton JA, Kuhlmann T, Antel J. The role of glial cells in multiple sclerosis disease progression. Nat Rev Neurol. 2022;18(4):237-248.
Cubas-Nunez L, Gil-Perotin S, Castillo-Villalba J, et al. Potential role of CHI3L1+ astrocytes in progression in MS. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e972.
Correale J, Farez MF. The role of astrocytes in multiple sclerosis progression. Front Neurol. 2015;6:180.
Abdelhak A, Benkert P, Schaedelin S, et al. Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol. 2023;80:1317-1325.
Tur C, Carbonell-Mirabent P, Cobo-Calvo A, et al. Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol. 2022;80:151.